Cargando…

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Mingying, Xu, Xiaoling, Fan, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126715/ https://www.ncbi.nlm.nih.gov/pubmed/34012925 http://dx.doi.org/10.3389/fonc.2021.672612

Ejemplares similares

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
por: Shen, Mo, et al.
Publicado: (2022)

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
por: Yang, Haitang, et al.
Publicado: (2019)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation
por: Jia, Daqi, et al.
Publicado: (2022)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis
por: Cai, Peiling, et al.
Publicado: (2023)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
por: Huffman, Kenneth E., et al.
Publicado: (2023)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
por: Xiang, Luochengling, et al.
Publicado: (2020)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
por: Kelly, William J., et al.
Publicado: (2018)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
por: Bulbul, Ajaz, et al.
Publicado: (2018)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
por: Boch, Christian, et al.
Publicado: (2013)

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance
por: Ma, Feng, et al.
Publicado: (2023)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
por: Chen, J, et al.
Publicado: (2013)

DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
por: Hu, Mangze, et al.
Publicado: (2020)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations
por: Kalari, Krishna R., et al.
Publicado: (2012)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oi8mbspjpsvtq3ofl1dguigqoi